Shares of Vertex Pharmaceuticals Incorporated (VRTX) were down 11.4% yesterday after the company announced data from a phase II study that evaluated its investigational, oral, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for treating people with painful lumbosacral radiculopathy (“LSR”), a form of peripheral neuropathic pain.Data from the study showed that treatment with suzetrigine led to a statistically significant and clinically meaningful within-group reduction in pain from baseline with ...